Lactoferrin for the developing brain: A promising milk protein? Event as iCalendar

05 February 2019

2 - 3pm

Venue: CBR Seminar Room 501-505

Location: Faculty of Medical and Health Sciences

Host: Centre for Brain Research

Contact email: sarah.j.evans@auckland.ac.nz

Stephane

Preterm infants and growth-restricted newborns are at high-risk of brain injury that can lead to severe neurological disorders, cognitive deficits and psychiatric diseases. There are currently no therapeutic interventions available to protect the brain of these high-risk infants.

Hypoxia-Ischemia, inflammation and fetal growth restriction are major triggers of preterm brain damage and altered brain development.

Lactoferrin ß (LF) has roles in the iron homeostasis and anti-inflammatory and antioxidant activities. A role of lactoferrin in brain development and cognition is also suggested.

Using different rodent models of developmental brain injuries, we have shown that lactoferrin given through lactation reduces inflammation, neuro-axonal apoptosis, and attenuated macro- and micro-structural alterations.

In conclusion, LF given as a supplement during lactation reduces acute and long-term cerebral alterations in chronic and acute developmental brain injury models. LF could play a key role in future neuroprotective strategies to protect the brain of the preterm and growth restricted infants.

Ochoa, T. J. and S. V. Sizonenko (2017). "Lactoferrin and prematurity: a promising milk protein?" Biochem Cell Biol 95(1): 22-30.

Professor Stéphane V. Sizonenko - Division of Development and Growth, Department of Pediatrics, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland.